Suscribirse

Antipyretics: mechanisms of action and clinical use in fever suppression - 03/09/11

Doi : 10.1016/S0002-9343(01)00834-8 
David M Aronoff, MD , a, Eric G Neilson, MD a
a Divisions of Infectious Diseases and Clinical Pharmacology and the Departments of Medicine and Cell Biology, Vanderbilt University School of Medicine, Nashville, Tennessee, USA 

*Requests for reprints should be addressed to David M. Aronoff, MD, Division of Clinical Pharmacology, 514 RRB, 23rd Avenue at Pierce, Nashville, Tennessee 37232-6603.

Abstract

Fever is a complex physiologic response triggered by infectious or aseptic stimuli. Elevations in body temperature occur when concentrations of prostaglandin E2 (PGE2) increase within certain areas of the brain. These elevations alter the firing rate of neurons that control thermoregulation in the hypothalamus. Although fever benefits the nonspecific immune response to invading microorganisms, it is also viewed as a source of discomfort and is commonly suppressed with antipyretic medication. Antipyretics such as aspirin have been widely used since the late 19th century, but the mechanisms by which they relieve fever have only been characterized in the last few decades. It is now clear that most antipyretics work by inhibiting the enzyme cyclooxygenase and reducing the levels of PGE2 within the hypothalamus. Recently, other mechanisms of action for antipyretic drugs have been suggested, including their ability to reduce proinflammatory mediators, enhance anti-inflammatory signals at sites of injury, or boost antipyretic messages within the brain. Although the complex biologic actions of antipyretic agents are better understood, the indications for their clinical use are less clear. They may not be indicated for all febrile conditions because some paradoxically contribute to patient discomfort, interfere with accurately assessing patients receiving antimicrobials, or predispose patients to adverse effects from other medications. The development of more selective fever-relieving agents and their prudent use with attention to possible untoward consequences are important to the future quality of clinical medicine.

El texto completo de este artículo está disponible en PDF.

Keywords : Acetaminophen, Antipyretics, Aspirin, Cyclooxygenase, Fever, Prostaglandins


Esquema


 Supported in part by Grants GM-15431, DK-46282, and GM-07569 from the National Institutes of Health, and the Tinsley Harrison Society.


© 2001  Excerpta Medica Inc. Reservados todos los derechos.
Añadir a mi biblioteca Eliminar de mi biblioteca Imprimir
Exportación

    Exportación citas

  • Fichero

  • Contenido

Vol 111 - N° 4

P. 304-315 - septembre 2001 Regresar al número
Artículo precedente Artículo precedente
  • Pitfalls in assessing the quality of care for patients with cardiovascular disease
  • Thomas G. DiSalvo, Sharon-Lise T. Normand, Paul J. Hauptman, Edward Guadagnoli, R.Heather Palmer, Barbara J. McNeil
| Artículo siguiente Artículo siguiente
  • Coronary vasospasm as a cause of effort-related myocardial ischemia during low-dose chronic continuous infusion of 5-fluorouracil
  • Chiara Lestuzzi, Elda Viel, Eugenio Picano, Nereo Meneguzzo

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.

¿Ya suscrito a @@106933@@ revista ?

@@150455@@ Voir plus

Mi cuenta


Declaración CNIL

EM-CONSULTE.COM se declara a la CNIL, la declaración N º 1286925.

En virtud de la Ley N º 78-17 del 6 de enero de 1978, relativa a las computadoras, archivos y libertades, usted tiene el derecho de oposición (art.26 de la ley), el acceso (art.34 a 38 Ley), y correcta (artículo 36 de la ley) los datos que le conciernen. Por lo tanto, usted puede pedir que se corrija, complementado, clarificado, actualizado o suprimido información sobre usted que son inexactos, incompletos, engañosos, obsoletos o cuya recogida o de conservación o uso está prohibido.
La información personal sobre los visitantes de nuestro sitio, incluyendo su identidad, son confidenciales.
El jefe del sitio en el honor se compromete a respetar la confidencialidad de los requisitos legales aplicables en Francia y no de revelar dicha información a terceros.


Todo el contenido en este sitio: Copyright © 2026 Elsevier, sus licenciantes y colaboradores. Se reservan todos los derechos, incluidos los de minería de texto y datos, entrenamiento de IA y tecnologías similares. Para todo el contenido de acceso abierto, se aplican los términos de licencia de Creative Commons.